Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma ( RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial

被引：2

作者：

Weisel, Katja ^{[1
]}

Dimopoulos, Meletios A. ^{[2
]}

San-Miguel, Jesus ^{[3
]}

Paner, Agne ^{[4
]}

Engelhardt, Monika ^{[5
]}

Taylor, Fiona ^{[6
]}

Lord-Bessen, Jennifer ^{[7
]}

Yao, David ^{[7
]}

Yip, Christine ^{[8
]}

Greenwood, Mike ^{[8
]}

Tang, Jackson ^{[7
]}

Cavo, Michele ^{[9
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[3] Univ Navarra Clin, Pamplona, Spain

[4] Rush Univ Med Ctr, Chicago, IL USA

[5] Univ Med Ctr Freiburg, Freiburg, Germany

[6] Adelphi Values, Boston, MA USA

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Adelphi Values, Bollington, England

[9] Bologna Univ, IRCCS Azienda Osped Univ Bologna, Seragnoli Inst Hematol, Sch Med, Bologna, Italy

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145310

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1662

引用

页数：6

共 50 条

[21] FINAL PHASE 2 STUDY DATA OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)
Palumbo, A.
Magarotto, V.
Sonneveld, P.
Plesner, T.
Paba-Prada, C.
Voorhees, P.
Mellqvist, U. H.
Byrne, C.
Harmenberg, J.
Nordstrom, E.
Zubair, H.
Richardson, P. G.
HAEMATOLOGICA, 2016, 101 : 85 - 85
[22] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
San Miguel, Jesus
Raab, Marc S.
Goldschmidt, Hartmut
Lonial, Sagar
Richardson, Paul G.
Shelat, Suresh
Bleickardt, Eric W.
Palumbo, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[23] Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
Mikhael, Joseph
Richardson, Paul G.
Usmani, Saad Zafar
Raje, Noopur S.
Bensinger, William
Dubin, Franck
Liu, Qianying
Vitse, Olivier
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[24] A health-related quality-of-life (HRQoL) analysis of pomalidomide plus low-dose dexamethasone plus daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.
Reece, Donna Ellen
Bahlis, Nizar J.
Samaras, Christy Joy
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddartha
Matous, Jeffrey
Song, Kevin W.
Seet, Christopher
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand Marquess
Fonseca, Gustavo A.
Agarwal, Amit
Chung, Weiyuan
Zafar, Faiza
Siegel, David Samuel DiCapua
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[25] A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients
Berenson, James
Martinez, Daisy
Spektor, Tanya
Sanchez, Armando
Ghermezi, Matthew
Swift, Regina
Eades, Benjamin
Schwartz, Gary
Eshaghian, Shahrooz
Lim, Stephen
Vescio, Robert
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E249 - E250
[26] Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
Song, Kevin W.
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Palumbo, Antonio
Belch, Andrew
Schey, Stephen
Sonneveld, Pieter
Sternas, Lars
Yu, Xin
Amatya, Ramesh
Monzini, Mara S.
Zaki, Mohamed
Jacques, Christian
Miguel, Jesus San
HAEMATOLOGICA, 2015, 100 (02) : E63 - E67
[27] Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone +/- subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
Terpos, Evangelos
Dimopoulos, Meletios A.
Boccadoro, Mario
Delimpasi, Sosana
Beksac, Meral
Katodritou, Eirini
Moreau, Philippe
Pompa, Alessandra
Symeonidis, Argiris
Bila, Jelena
Oriol, Albert
Mateos, Maria-Victoria
Einsele, Hermann
Orfanidis, Ioannis
Gries, Katharine S.
Fastenau, John
Liu, Kevin
He, Jianming
Kampfenkel, Tobias
Qiu, Yanping
Amin, Himal
Carson, Robin
Sonneveld, Pieter
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (04) : 481 - 490
[28] Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial
Song, Kevin W.
Dimopoulos, Meletios A.
Weisel, Katja
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Spencer, Andrew
Knop, Stefan
Renner, Christoph
Bahlis, Nizar J.
Amatya, Ramesh
Yu, Xin
Monzini, Mara Silvia
Sternas, Lars
Zaki, Mohamed H.
Jacques, Christian J.
San Miguel, Jesus F.
BLOOD, 2013, 122 (21)
[29] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis
Oriol, Albert
Richardson, Paul G.
Mateos, Maria-Victoria
Larocca, Alessandra
Creixenti, Joan Blade
Cavo, Michele
Rodriguez-Otero, Paula
Norkin, Maxim
Nadeem, Omar
Hiemenz, John W.
Hassoun, Hani
Touzeau, Cyrille
Amor, Adrian Alegre
Paner, Agne
Maisel, Christopher
Mazumder, Amitabha
Raptis, Anastasios
Puig, Noemi
Strang, Peter
Sandberg, Anna
Jaques, Christian
Thuresson, Marcus
Orre, Marie
Leleu, Xavier
BLOOD, 2020, 136
[30] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Mikhael, Joseph
Usmani, Saad Z.
Raje, Noopur
Bensinger, William
Kanagavel, Dheepak
Gao, Lei
Ziti-Ljajic, Samira
Anderson, Kenneth C.
BLOOD, 2017, 130

← 1 2 3 4 5 →